AroCell AB: Interim report January - June 2016
August 25 2016 - 2:45AM
Interim report, 1 January - 30
June 2016
-
Net sales were TSEK 0
(0)
-
Loss after financial items was
TSEK -4,804 (-4,046)
-
Earnings per share where SEK
-0.17 (-0.17)
-
Cash flow from operating
activities was TSEK -2,501 (-3,793)
Reporting period, 1 April - 30
June 2016
-
Net sales were TSEK 0
(0)
-
Loss after financial items was
TSEK -1,962 (-1,644)
-
Cash flow from operating
activities was TSEK -1,229 (-530)
-
Christine Tadgell elected to
the board of directors
-
Collaboration agreement signed
and clinical study initiated at the Stockholm South General
Hospital regarding follow-up of prostate cancer patients with TK
210 ELISA test
-
Collaboration agreement signed
and clinical study initiated at the University Hospital of Helsinki
regarding follow-up of sarcoma patients with TK 210 ELISA
test
-
Martin Shaw appointed as
Business Development Manager
-
New patent confirmed which
strengthens the AroCell patent portfolio
-
AroCell listed on Nasdaq First
North on June 30
About AroCell
AroCell AB (publ) is a Swedish company that
develops standardized modern blood tests to support the prognosis
and follow up of cancer patients. AroCell's new technology is based
on patented methods to measure TK1 protein levels, which provide
valuable information about the speed of cell turnover. A tumor has
high cell turnover (speed of cell division and cell death) and as a
result TK1 can be detected in the blood with a simple laboratory
test, called TK 210 ELISA. The test provides valuable clinical
information for prognosis and optimization of treatment strategy.
The test may also be used for monitoring disease relapse. AroCell
(AROC) is listed at Nasdaq First North and has about 2 700
shareholders. For more information, please see
www.arocell.com.
This information is information
that AroCell is obliged to make public pursuant to the EU Market
Abuse Regulation and the Securities Markets Act. The information
was submitted for publication, through Jan Stålemark, at 08:45 on
25 August 2016. Redeye AB is AroCell:s Certified Adviser.
Significant events during the reporting
period
- Christine Tadgell elected to the board of
directors. Christine is VP, General Manager, Commercial Division at
inVentiv Health.
- The collaboration agreement was signed with the
Stockholm South General Hospital for the clinical study on patients
with prostate cancer which will be evaluated from diagnosis through
treatment and follow-up with the TK 210 ELISA test. The study is
estimated to take two years.
- The collaboration agreement was signed with the
University Hospital of Helsinki approved clinical study regarding
sarcoma cancer patients. The patients will be evaluated with the TK
210 ELISA test. The study is estimated to take two years.
- Martin Shaw appointed as Business Development
Manager to the management team. Martin Shaw has over 40 years'
experience in the development and introduction of novel biomarker
assays, to the pharmaceutical, biotechnology and laboratory
medicine industries.
- The European Patent Office has confirmed the
grant of a patent to AroCell regarding an invention relating to
exposed thymidine kinase 1 (TK1) derived peptides, ligands and
methods employing these.
- AroCell listed on Nasdaq First North on June
30.
Significant events after the
reporting period
AroCell Interim report 2016 Q2 Eng,
PDF
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: AroCell AB via Globenewswire
Archrock (NYSE:AROC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Archrock (NYSE:AROC)
Historical Stock Chart
From Sep 2023 to Sep 2024